Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Pelthos Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
PELTHOS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
Mi | Ligand, Pelthos Close Merger Deal With Channel's CHRO; To Launch ZELSUVMI In July | 304 | AFX News | WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) and Pelthos Therapeutics Inc. announced Wednesday the closing of the previously announced merger agreement with Channel Therapeutics... ► Artikel lesen | |
Mi | Ligand schließt Fusion ab, Pelthos bringt Molluscum-Behandlung auf den Markt | 5 | Investing.com Deutsch | ||
Mi | Ligand completes merger, Pelthos to launch molluscum treatment | 2 | Investing.com | ||
Mi | Ligand Pharmaceuticals: Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics | 118 | GlobeNewswire (Europe) | Pelthos plans to launch ZELSUVMI for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company... ► Artikel lesen | |
27.06. | Channel Therapeutics announces 10-for-1 reverse split ahead of NYSE American uplisting | 2 | Seeking Alpha | ||
27.06. | Channel Therapeutics Corporation: Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement | 109 | GlobeNewswire (Europe) | FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), an emerging leader in the development of non-opioid pain treatment... ► Artikel lesen | |
14.05. | EXCLUSIVE: Channel Therapeutics Touts Positive Efficacy Results For Eye Treatment Potential In Multiple Preclinical In Vivo Models | 2 | Benzinga.com | ||
13.05. | Channel Therapeutics Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
01.05. | Channel Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
01.05. | Channel Therapeutics Corporation: Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules | 1 | GlobeNewswire (USA) | ||
17.04. | Ligand's Pelthos unit joins forces with Channel Therapeutics in merger centered on launch of molluscum gel Zelsuvmi | 1 | FiercePharma | ||
17.04. | Ligand unit Pelthos to merge with Channel Therapeutics | 1 | Seeking Alpha | ||
17.04. | Ligand, Channel Therapeutics Agree To Combine Pelthos, LNHC With CHRO Merger Sub | 409 | AFX News | WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) Thursday announced a definitive merger agreement with Channel Therapeutics Corp. (CHRO) to combine Ligand's wholly owned subsidiaries... ► Artikel lesen | |
17.04. | Channel Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
17.04. | Ligand Pharmaceuticals: Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics | 272 | GlobeNewswire (Europe) | Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI ZELSUVMI is an FDA-designated novel drug... ► Artikel lesen | |
27.03. | Channel Therapeutics Corp - 10-K, Annual Report | 2 | SEC Filings | ||
03.03. | Channel Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
20.12.24 | Channel Therapeutics Corporation: Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine | 186 | GlobeNewswire (Europe) | FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics... ► Artikel lesen | |
18.12.24 | Channel Therapeutics Corporation: Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model | 196 | GlobeNewswire (Europe) | FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,116 | -1,19 % | Übernahmefieber! BioTech und Künstliche Intelligenz beflügelt Evotec, NetraMark Holdings, NovoNordisk und Bayer | Derzeit erlebt der Biotech-Sektor eine spannende Transformation: Denn Big Data und Künstliche Intelligenz verändern in rasanter Art und Weise, wie neue Medikamente entdeckt, entwickelt und getestet... ► Artikel lesen | |
VALNEVA | 2,382 | -6,15 % | UNGLAUBLICHE Sondermeldung bei Valneva Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
MAINZ BIOMED | 1,430 | 0,00 % | Mainz BioMed NV: Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test | BERKELEY, Calif. and MAINZ, Germany, June 25, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
QIAGEN | 40,745 | -0,95 % | Dividendenbekanntmachungen (02.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AECOM US00766T1007 0,26 USD 0,2202 EUR AMADEUS IT GROUP SA ES0109067019 - 0,89 EUR ASSECO SOUTH EASTERN EUROPE SA PLASSEE00014 1... ► Artikel lesen | |
COGENT BIOSCIENCES | 9,865 | +28,28 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen | |
APOGEE THERAPEUTICS | 40,140 | -14,10 % | Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis | APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% placebo-adjusted)... ► Artikel lesen | |
BIONTECH | 93,75 | -0,64 % | Moderna mit Erfolg in Phase 3: Grippeimpfstoff des BioNTech-Konkurrenten zeigt Wirkung | Moderna hat in einer Phase-3-Studie zur Wirksamkeit des saisonalen Grippeimpfstoff-Kandidaten mRNA-1010 positive Ergebnisse erzielt. In der Studie mit über 40.000 Teilnehmern ab 50 Jahren zeigte mRNA-1010... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,040 | -5,00 % | Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith? | ||
CUREVAC | 4,590 | +0,26 % | UNGLAUBLICHE Sondermeldung bei CureVac Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
REGENCELL BIOSCIENCE | 26,390 | +9,50 % | Regencell Bioscience Stock Soars 140% | ||
QUANTUM-SI | 1,880 | 0,00 % | Quantum-Si stock falls after pricing capital raise of $50M via stock offering | ||
VERVE THERAPEUTICS | 11,230 | -0,13 % | Aktien New York Schluss: Verluste - Sorgen um Krieg in Nahost nehmen zu | NEW YORK (dpa-AFX) - Die sich zuspitzende Lage in Nahost und die Unsicherheit über das weitere Vorgehen der USA haben am Dienstag die US-Börsen belastet. Der New Yorker Leitindex Dow Jones Industrial... ► Artikel lesen | |
BEAM THERAPEUTICS | 19,480 | -2,31 % | H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT | ||
MUSTANG BIO | 4,180 | +248,33 % | Mustang Bio-Aktie steigt stark an nach FDA-Sonderstatus für Hirntumor-Therapie | ||
SANA BIOTECHNOLOGY | 3,140 | -0,95 % | Morgan Stanley initiates Sana Biotechnology stock with Overweight rating |